00272-5/assets/gr2.jpg)
Disease specific survival for patients in good prognostic and poor prognostic groups on orchiectomy plus Anandron®/nilutamide (A) or plus placebo (P) represented as a log (time in months) (a) and as time (months) (b). Anandron and good prognostic: 77 patients; placebo and good prognostic: 85 patients; Anandron and poor prognostic: 116 patients; placebo and poor prognostic: 121 patients.
Copyright © 